Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MOA Life Plus Co. Ltd. Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.	South Korea	142760
Moberg Pharma Develops & commercializes a leading topical treatment for nail fungus for European markets.	Sweden	MOB
Mochida Pharmaceutical Co.,Ltd. An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.	Japan	4534
Moderna, Inc. Pioneering mRNA science to create transformative medicines and vaccines for diverse diseases.	United States of America	MRNA
Monopar Therapeutics Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.	United States of America	MNPR
Monte Rosa Therapeutics, Inc. Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.	United States of America	GLUE
Moogene Medi Co., Ltd. Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.	South Korea	322970
MORISHITA JINTAN CO.,LTD. Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.	Japan	4524
MUROMACHI CHEMICALS INC. A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.	Japan	4885
MUSTANG BIO, INC. Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.	United States of America	MBIO